San Ramon, CA, USA, May 23, 2018 / B3C newswire / -- rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
Manufacturers who wish to participate in this great opportunity should contact rfxcel (This email address is being protected from spambots. You need JavaScript enabled to view it.) for details of the solution and terms of the offer. They then simply need to name rfxcel as their Gateway Provider when registering on the EMVO portal before June 15th 2018. When we conclude a software contract, the cost of the EMVO fee will be absorbed by rfxcel as a discount.
With EMVO onboarding fees increasing by 50% after June 15th 2018, rfxcel is taking a significant step in helping EMVO to accelerate its onboarding programme and MAHs to meet their requirements under the Falsified Medicines Directive in a timely manner.
rfxcel provides a full-service, fixed price approach that gets MAHs ready to exchange data with EMVO quickly and efficiently. We manage the end to end process from EMVO onboarding to connection, reporting and interaction with business partners such as contract manufacturers (CMOs). This enables even very small MAH companies to comply with FMD obligations with minimum resource and cost impact.
“Our initiative to cover the cost of the EMVO onboarding fee, paired with our rapid, full-service implementation, provides a great opportunity to MAHs who need move quickly. With rfxcel they also avoid the hidden costs and additional resources required by other solution providers to onboard their trading partners”, said Mark Davison, rfxcel Senior Director of Operations Europe.
To learn more about the requirements surrounding the European Union’s Falsified Medicines Directive (FMD) or rfxcel’s solutions to meet these needs, please contact us.
*The offer relates to EMVO (one-time) onboarding fees only. It does not include any initial or annual fees that may be payable to national medicine verification organisations (NMVOs).
About rfxcel
rfxcel is the leading provider of SaaS-based track and trace solutions, with offices worldwide and EU headquarters in the United Kingdom. Their platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. rfxcel’s relentless commitment to customer success and continuous innovation ensures that companies can meet today’s requirements and tomorrow’s challenges.
Contact
Herb Wong
VP Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
rfxcel.com